GoAI
Get started
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc.

FTH

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$34.795

+$2.795 · +8.73%

Aug 24, 12:49 PM ET

FTH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

42

Fair Value

Momentum

89

Strong Up

Sentiment

65

Bullish

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Anand Parikh
Listed since
Feb 4, 2021
Employees
29

Market position

Day range

Current $34.795

52-week range

Current $34.795

Open
$32.80
Previous close
$32.00
Volume
125.56K
0.85× average
Average volume
147.52K
Average daily volume
Market cap
896.97M USD
Beta
-0.31
Market reference 1
50-day average
$26.4108
+31.75% above average
200-day average
$20.3802
+70.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.25×
P/B (TTM)
1.14×
P/S (TTM)
-184.9×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
2740.82%
Operating margin
4098.54%
Net margin
4030.69%

Financial health

Debt / equity
0×

Financial statements

Income trends

Operating income

−22.29M USD+29.61%

Net income

−21.09M USD+30.08%
Income trends across reported periods−18.28M USD−29.5M USD−40.71M USD−51.92M USDOperating income, FY2021: −37.48M USDOperating income, FY2022: −49.12M USDOperating income, FY2023: −37.06M USDOperating income, FY2024: −31.66M USDOperating income, FY2025: −22.29M USDNet income, FY2021: −36.79M USDNet income, FY2022: −48.59M USDNet income, FY2023: −34.1M USDNet income, FY2024: −30.16M USDNet income, FY2025: −21.09M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −37.48M USD. Operating income FY2022 −49.12M USD. Operating income FY2023 −37.06M USD. Operating income FY2024 −31.66M USD. Operating income FY2025 −22.29M USD. Net income FY2021 −36.79M USD. Net income FY2022 −48.59M USD. Net income FY2023 −34.1M USD. Net income FY2024 −30.16M USD. Net income FY2025 −21.09M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—551K USD571K USD1.81M USD685K USD
Gross profit—−551K USD−571K USD−1.81M USD−685K USD
Research and development10.96M USD18.63M USD18.3M USD29.58M USD21.66M USD
Selling, general, and administrative11.33M USD12.49M USD18.77M USD17.73M USD15.14M USD
Operating expenses22.29M USD31.11M USD36.49M USD47.31M USD36.8M USD
Interest income1.24M USD2.55M USD3.62M USD1.78M USD800K USD
Interest expense32K USD90K USD144K USD219K USD670K USD
Depreciation and amortization139K USD551K USD3.68M USD1.81M USD685K USD
Operating income−22.29M USD−31.66M USD−37.06M USD−49.12M USD−37.48M USD
Net income−21.09M USD−30.16M USD−34.1M USD−48.59M USD−36.79M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$56.50

62.38% upside
Past 12 months12-month forecastHigh $60.00Average $56.50Low $50.00

FTH news

zacks.com

Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know

The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in…

Read source
businesswire.com

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S.…

Read source
businesswire.com

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor…

Read source
businesswire.com

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted two new employees options to purchase an aggregate of 11,000…

Read source
gurufocus.com

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference

Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pa

Read source
businesswire.com

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present…

Read source

FTH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding FTH

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
275.53K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.85-0.68%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
103.49K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$197.26-0.45%

Continue in GoAI

Research FTH

research.disclaimer